These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 32746624

  • 1. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV.
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [Abstract] [Full Text] [Related]

  • 2. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M, Chiu MN, Pilkhwal Sah S.
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME.
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V.
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS.
    J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
    [Abstract] [Full Text] [Related]

  • 9. Cutaneous immune-related adverse events to checkpoint inhibitors.
    Malviya N, Tattersall IW, Leventhal J, Alloo A.
    Clin Dermatol; 2020 Apr; 38(6):660-678. PubMed ID: 33341200
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
    Storgard R, Markova A.
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
    [Abstract] [Full Text] [Related]

  • 12. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
    Emonet C, Tétart F, Bauvin O, Cellier L, Courville P, Mignard C, Janela-Lapert R, Lefebvre A, Lachkar S, Lechevalier D, Lagarce L, Carvalho P, Tedbirt B.
    J Immunother; 2024 May; 46(2):59-63. PubMed ID: 36622668
    [Abstract] [Full Text] [Related]

  • 13. Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
    Satoh TK, Neulinger MM, Stadler PC, Aoki R, French LE.
    J Dermatol; 2024 Jan; 51(1):3-11. PubMed ID: 38031902
    [Abstract] [Full Text] [Related]

  • 14. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, Segura S, Freites-Martinez A, Lallas K, Romano MC, Oikonomou C, Starace M, Dimopoulos MA, Kyrgidis A, Lazaridou E, Giavedoni P, Annunziata MC, Peris K, Echeverría M, Lopez-Tujillo E, Syrigos K, Papageorgiou C, Podlipnik S, Fabbrocini G, Torre AC, Kemanetzi C, Villa-Crespo L, Lallas A, Stratigos AJ, Sibaud V.
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [Abstract] [Full Text] [Related]

  • 15. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
    Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, Motzer RJ, Busam KJ, Lacouture ME.
    Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
    [Abstract] [Full Text] [Related]

  • 16. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A, Edwards C, Patel P, Heywood RM, Gupta A, Mann J, Harland C, Heelan K, Larkin J, Lorigan P, Harwood CA, Matin RN, Fearfield L.
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
    Maloney NJ, Ravi V, Cheng K, Bach DQ, Worswick S.
    Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.